FDA Approves Pfizer and Arvinas Breast Cancer Drug
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy PFE?
Source: Newsfilter
- New Drug Approval: The FDA has approved Veppanu, a breast cancer drug developed by Pfizer and Arvinas, specifically designed for advanced patients with a specific genetic mutation, marking a significant advancement in treatment options.
- Clinical Trial Results: In a late-stage trial involving 624 participants, Veppanu demonstrated a significant extension in the duration of patients' survival without disease progression compared to the traditional hormone therapy fulvestrant, indicating competitive efficacy.
- Market Outlook: Arvinas CEO Randy Teel stated that Veppanu provides a much-needed treatment option for stage-4 breast cancer patients, with plans to announce a commercialization deal in the coming weeks to clarify pricing strategies.
- Companion Test Approval: The FDA also approved the Guardant360 CDx blood test to identify patients carrying the ESR1 mutation, ensuring the drug's targeted application and enhancing treatment effectiveness.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 26.700
Low
24.00
Averages
28.56
High
35.00
Current: 26.700
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer Secures Patent Extension for Vyndamax with Generic Drugmakers
- Patent Protection Extended: Pfizer has reached a settlement with Hikma, Cipla, and Dexcel to extend the patent protection for Vyndamax until June 2031, providing the company with additional time to develop new blockbuster drugs, thereby enhancing its market competitiveness.
- Revenue Growth Support: Vyndamax and its related drugs generated $6.3 billion in revenue for Pfizer in 2025, reflecting a 17% increase and accounting for 10% of total revenue, indicating that Pfizer can maintain revenue stability despite slowing COVID vaccine sales.
- Market Expectation Adjustment: Analysts had anticipated a decline in Vyndamax revenue starting in 2029; however, the settlement delays the launch of generics, giving Pfizer two more years to fill this revenue gap, ensuring future income sources.
- Strategic Development Outlook: By securing Vyndamax's patent, Pfizer provides investors with a clear outlook for the next five years, and combined with the expansion of its respiratory vaccine portfolio, new GLP-1 obesity drugs, and cancer medications, it may achieve stable growth again.
See More
FDA Approves Pfizer and Arvinas Breast Cancer Drug
- New Drug Approval: The FDA has approved Veppanu, a breast cancer drug developed by Pfizer and Arvinas, specifically designed for advanced patients with a specific genetic mutation, marking a significant advancement in treatment options.
- Clinical Trial Results: In a late-stage trial involving 624 participants, Veppanu demonstrated a significant extension in the duration of patients' survival without disease progression compared to the traditional hormone therapy fulvestrant, indicating competitive efficacy.
- Market Outlook: Arvinas CEO Randy Teel stated that Veppanu provides a much-needed treatment option for stage-4 breast cancer patients, with plans to announce a commercialization deal in the coming weeks to clarify pricing strategies.
- Companion Test Approval: The FDA also approved the Guardant360 CDx blood test to identify patients carrying the ESR1 mutation, ensuring the drug's targeted application and enhancing treatment effectiveness.
See More
Analysis of Upcoming U.S. Jobs Report Outlook
- Job Market Expectations: According to FactSet consensus estimates, the U.S. is expected to add only 50,000 jobs in April, significantly lower than March's 178,000, indicating signs of economic slowdown that could impact investor confidence.
- Unemployment Rate Stability: The unemployment rate is anticipated to remain steady at 4.3%, suggesting that despite the decrease in job additions, the labor market remains relatively stable, potentially alleviating fears of an economic downturn.
- GDP Growth Situation: The U.S. GDP grew at a seasonally adjusted annualized rate of 2% in the first quarter, higher than the fourth quarter's 0.5% but below the 2.2% estimate, reflecting economic sluggishness that may influence future monetary policy decisions.
- Market Volatility: Despite a strong performance in April, with the S&P 500 and Nasdaq hitting record highs, investors should remain cautious of the upcoming
See More
FDA Approves First PROTAC Therapy for Breast Cancer
- FDA Approval Milestone: The FDA's approval of Veppanu marks the first authorization of a PROTAC therapy for breast cancer, representing a significant advancement in targeted protein-degrading drugs and offering new treatment options for patients.
- Clinical Trial Success: In a Phase 3 trial, Veppanu demonstrated a 43% reduction in the risk of disease progression or death compared to Fulvestrant, with median progression-free survival improving from 2.1 months to 5 months, indicating substantial efficacy.
- Commercial Rollout Strategy: Arvinas and Pfizer plan to collaborate with a third party to support the commercial rollout of Veppanu, which is expected to expedite the drug's market introduction and address patient needs effectively.
- Positive Market Reaction: Following the FDA approval announcement, Arvinas' shares surged nearly 10%, although the stock has declined 11% year-to-date; investor sentiment remains bullish regarding the drug's long-term prospects.
See More
VEPPANU Receives FDA Approval, Pioneering PROTAC Therapy Era
- FDA Approval Milestone: Arvinas and Pfizer's VEPPANU has received FDA approval as the first PROTAC therapy for ER+/HER2-, ESR1-mutated advanced breast cancer, marking a significant breakthrough in treatment options and expected to greatly improve patient outcomes.
- Clinical Trial Results: In the VERITAC-2 trial, VEPPANU demonstrated a statistically significant 43% improvement in progression-free survival compared to standard treatment fulvestrant, with a median PFS of 5 months, indicating its potential in treating resistant breast cancer.
- Broad Market Potential: The FDA's early approval not only marks Arvinas' first approved drug but also strengthens confidence in its clinical pipeline across oncology and neurodegenerative diseases, likely attracting more investment and partnership opportunities.
- Commercialization Plans: Arvinas and Pfizer plan to select a third-party partner to maximize VEPPANU's commercial potential, which is expected to accelerate the market introduction of this new therapy to meet the urgent demand for new treatment options.
See More
FDA Approves Breast Cancer Therapy Developed by Pfizer and Arvinas
- New Drug Approval: The FDA approved vepdegestrant, a breast cancer therapy developed by Pfizer and Arvinas, marking a significant new treatment option for late-stage breast cancer patients, which is expected to enhance patient care.
- Significant Efficacy: In the VERITAC-2 Phase 3 clinical trial, patients treated with vepdegestrant experienced a progression-free survival of five months compared to just 2.1 months for those on the established drug fulvestrant, demonstrating the drug's superior efficacy.
- Companion Diagnostic Approved: The FDA also authorized the Guardant360 CDx companion diagnostic device developed by Guardant Health, aimed at identifying breast cancer patients with ESR1 mutations, thereby improving treatment precision and effectiveness.
- Broad Market Potential: This approval not only opens new market opportunities for Pfizer and Arvinas but may also foster further collaboration and innovation in breast cancer treatment, enhancing their competitive position in the biopharmaceutical market.
See More
Pfizer Secures Patent Extension for Vyndamax with Generic Drugmakers
- Patent Protection Extended: Pfizer has reached a settlement with Hikma, Cipla, and Dexcel to extend the patent protection for Vyndamax until June 2031, providing the company with additional time to develop new blockbuster drugs, thereby enhancing its market competitiveness.
- Revenue Growth Support: Vyndamax and its related drugs generated $6.3 billion in revenue for Pfizer in 2025, reflecting a 17% increase and accounting for 10% of total revenue, indicating that Pfizer can maintain revenue stability despite slowing COVID vaccine sales.
- Market Expectation Adjustment: Analysts had anticipated a decline in Vyndamax revenue starting in 2029; however, the settlement delays the launch of generics, giving Pfizer two more years to fill this revenue gap, ensuring future income sources.
- Strategic Development Outlook: By securing Vyndamax's patent, Pfizer provides investors with a clear outlook for the next five years, and combined with the expansion of its respiratory vaccine portfolio, new GLP-1 obesity drugs, and cancer medications, it may achieve stable growth again.
See More
FDA Approves Pfizer and Arvinas Breast Cancer Drug
- New Drug Approval: The FDA has approved Veppanu, a breast cancer drug developed by Pfizer and Arvinas, specifically designed for advanced patients with a specific genetic mutation, marking a significant advancement in treatment options.
- Clinical Trial Results: In a late-stage trial involving 624 participants, Veppanu demonstrated a significant extension in the duration of patients' survival without disease progression compared to the traditional hormone therapy fulvestrant, indicating competitive efficacy.
- Market Outlook: Arvinas CEO Randy Teel stated that Veppanu provides a much-needed treatment option for stage-4 breast cancer patients, with plans to announce a commercialization deal in the coming weeks to clarify pricing strategies.
- Companion Test Approval: The FDA also approved the Guardant360 CDx blood test to identify patients carrying the ESR1 mutation, ensuring the drug's targeted application and enhancing treatment effectiveness.
See More
Analysis of Upcoming U.S. Jobs Report Outlook
- Job Market Expectations: According to FactSet consensus estimates, the U.S. is expected to add only 50,000 jobs in April, significantly lower than March's 178,000, indicating signs of economic slowdown that could impact investor confidence.
- Unemployment Rate Stability: The unemployment rate is anticipated to remain steady at 4.3%, suggesting that despite the decrease in job additions, the labor market remains relatively stable, potentially alleviating fears of an economic downturn.
- GDP Growth Situation: The U.S. GDP grew at a seasonally adjusted annualized rate of 2% in the first quarter, higher than the fourth quarter's 0.5% but below the 2.2% estimate, reflecting economic sluggishness that may influence future monetary policy decisions.
- Market Volatility: Despite a strong performance in April, with the S&P 500 and Nasdaq hitting record highs, investors should remain cautious of the upcoming
See More
FDA Approves First PROTAC Therapy for Breast Cancer
- FDA Approval Milestone: The FDA's approval of Veppanu marks the first authorization of a PROTAC therapy for breast cancer, representing a significant advancement in targeted protein-degrading drugs and offering new treatment options for patients.
- Clinical Trial Success: In a Phase 3 trial, Veppanu demonstrated a 43% reduction in the risk of disease progression or death compared to Fulvestrant, with median progression-free survival improving from 2.1 months to 5 months, indicating substantial efficacy.
- Commercial Rollout Strategy: Arvinas and Pfizer plan to collaborate with a third party to support the commercial rollout of Veppanu, which is expected to expedite the drug's market introduction and address patient needs effectively.
- Positive Market Reaction: Following the FDA approval announcement, Arvinas' shares surged nearly 10%, although the stock has declined 11% year-to-date; investor sentiment remains bullish regarding the drug's long-term prospects.
See More
VEPPANU Receives FDA Approval, Pioneering PROTAC Therapy Era
- FDA Approval Milestone: Arvinas and Pfizer's VEPPANU has received FDA approval as the first PROTAC therapy for ER+/HER2-, ESR1-mutated advanced breast cancer, marking a significant breakthrough in treatment options and expected to greatly improve patient outcomes.
- Clinical Trial Results: In the VERITAC-2 trial, VEPPANU demonstrated a statistically significant 43% improvement in progression-free survival compared to standard treatment fulvestrant, with a median PFS of 5 months, indicating its potential in treating resistant breast cancer.
- Broad Market Potential: The FDA's early approval not only marks Arvinas' first approved drug but also strengthens confidence in its clinical pipeline across oncology and neurodegenerative diseases, likely attracting more investment and partnership opportunities.
- Commercialization Plans: Arvinas and Pfizer plan to select a third-party partner to maximize VEPPANU's commercial potential, which is expected to accelerate the market introduction of this new therapy to meet the urgent demand for new treatment options.
See More
FDA Approves Breast Cancer Therapy Developed by Pfizer and Arvinas
- New Drug Approval: The FDA approved vepdegestrant, a breast cancer therapy developed by Pfizer and Arvinas, marking a significant new treatment option for late-stage breast cancer patients, which is expected to enhance patient care.
- Significant Efficacy: In the VERITAC-2 Phase 3 clinical trial, patients treated with vepdegestrant experienced a progression-free survival of five months compared to just 2.1 months for those on the established drug fulvestrant, demonstrating the drug's superior efficacy.
- Companion Diagnostic Approved: The FDA also authorized the Guardant360 CDx companion diagnostic device developed by Guardant Health, aimed at identifying breast cancer patients with ESR1 mutations, thereby improving treatment precision and effectiveness.
- Broad Market Potential: This approval not only opens new market opportunities for Pfizer and Arvinas but may also foster further collaboration and innovation in breast cancer treatment, enhancing their competitive position in the biopharmaceutical market.
See More
